thrombosis

TAVI en insuficiencia aórtica pura, nuevos dispositivos con nuevos resultados

We Must Still Fear the “Big Five Complications” After TAVR

Surgical risk scores cannot be used for transcatheter aortic valve replacement (TAVR) and they usually overestimate procedural risk. There are 5 big complications after TAVR, specifically, that cannot be predicted by conventional surgical scores. &nbsp; These 5 peri-procedural complications are considered important because they have a somewhat significant impact on survival after TAVR. &nbsp; They are: 1)<a href="https://solaci.org/en/2019/04/01/we-must-still-fear-the-big-five-complications-after-tavr/" title="Read more" >...</a>

ACC 2019 | STOPDAPT-2: Monoterapia con P2Y12 luego de un corto período de doble antiagregación post angioplastia

ACC 2019 | STOPDAPT-2: P2Y12 Monotherapy After Short-Term Dual Antiplatelet Therapy After Angioplasty

Aspirin is against the ropes: first, it was primary prevention; now, its use is being reconsidered even in relation to angioplasty. There might be paradigm changes as regards antiplatelet therapy after angioplasty. These two studies presented at the American College of Cardiology (ACC) 2019 Scientific Session can really change what we have been doing unquestioningly<a href="https://solaci.org/en/2019/03/25/acc-2019-stopdapt-2-p2y12-monotherapy-after-short-term-dual-antiplatelet-therapy-after-angioplasty/" title="Read more" >...</a>

ACC 2019 | POET: los antibióticos vía oral con buenos resultados a largo plazo en endocarditis

ACC 2019 | AUGUSTUS: Apixaban Plus P2Y12 Inhibitor Is the Best Combination in Atrial Fibrillation and Angioplasty

Aspirin increases bleeding with no ischemic benefit, but a trend toward more stent thrombosis with placebo warrants further studies. Patients with atrial fibrillation who receive an anticoagulant agent and coronary angioplasty with a stent, and then continue with aspirin, experience an increased risk of bleeding without any ischemic benefit whatsoever. &nbsp; The use of a<a href="https://solaci.org/en/2019/03/25/acc-2019-augustus-apixaban-plus-p2y12-inhibitor-is-the-best-combination-in-atrial-fibrillation-and-angioplasty/" title="Read more" >...</a>

ACC 2019 | Prometedores resultados para el TAVI en bajo riesgo

ACC 2019 | TAVR in Low-Risk Patients Is Noninferior

Courtesy of Dr. Carlos Fava. Self-expanding supraannular aortic valves have proved to be superior to surgery in high-risk patients and noninferior in intermediate-risk patients. However, the current challenge is posed by low-risk, generally younger, patients. In that sense, our purpose is to determine device effectiveness and safety in terms of mortality and stroke rates (which are<a href="https://solaci.org/en/2019/03/19/acc-2019-tavr-in-low-risk-patients-is-noninferior/" title="Read more" >...</a>

DES de 2.0 mm para vasos muy pequeños: ¿Es viable?

Drug eluting Stents vs. Drug Coated Balloons for In-Stent Restenosis

The rationale behind the decision to not add another layer of metal to the artery sounded attractive and this was what paved the way for drug coated balloons as an alternative strategy to treat in-stent restenosis. “We’ve already got a stent in place, we only have to dilate and leave the drug” is what we<a href="https://solaci.org/en/2019/03/14/drug-eluting-stents-vs-drug-coated-balloons-for-in-stent-restenosis/" title="Read more" >...</a>

stent

Abluminal Sirolimus and luminal CD34 antibody layer: Is COMBO the Future of Stents?

This large cohort of patients treated with the dual therapy COMBO stent has showed excellent outcomes after one year (MASCOT Post Marketing Registry). Long term follow up is still ongoing. The COMBO stent is a new device with an abluminal sirolimus biodegradable polymer and a luminal layer of antibodies that promotes endothelial healing (anti CD34+)<a href="https://solaci.org/en/2019/03/11/abluminal-sirolimus-and-luminal-cd34-antibody-layer-is-combo-the-future-of-stents/" title="Read more" >...</a>

Anillos aórticos pequeños, ¿Qué válvula deberíamos elegir?

NOTION and UK TAVI Report Good Long-Term Outcomes

Both studies followed beyond 5 years patients with severe aortic stenosis who had undergone transcatheter aortic valve replacement (TAVR). Findings included low rates of significant valve degeneration and failure, in both cases. While data on the long-term degeneration of transcatheter-implanted valves are scarce, follow-up from the NOTION trial of low-risk patients and from the UK TAVI<a href="https://solaci.org/en/2019/02/12/notion-and-uk-tavi-report-good-long-term-outcomes/" title="Read more" >...</a>

Lo más leído en Enfermedades Vasculares Periféricas

The Most Relevant Articles of 2018 in Peripheral Vascular Disease

1- What’s New in the European Guidelines on Peripheral Arterial Disease Since the last version of the European guidelines on the diagnosis and treatment of peripheral arterial disease in 2011, there have been many trials and registries that warrant guideline adjustments in many aspects. The first novelty is the teamwork that gave way to these<a href="https://solaci.org/en/2019/02/04/the-most-relevant-articles-of-2018-in-peripheral-vascular-disease/" title="Read more" >...</a>

Infarto agudo de miocardio y lesiones de múltiples niveles

The Ten Commandments for the Fourth Universal Definition of Infarction

The Fourth Universal Definition of Myocardial Infarction is a document developed jointly by the European Society of Cardiology (ESC), the American College of Cardiology (ACC), the American Heart Association (AHA), and the World Heart Federation (WHF). The Fourth Definition was necessary for multiple reasons, including increasingly higher troponin sensitivity. &nbsp; While troponin obviously does not<a href="https://solaci.org/en/2019/01/30/the-ten-commandments-for-the-fourth-universal-definition-of-infarction/" title="Read more" >...</a>

The Most Relevant Articles of 2018 in Pharmacology and Clinical Cardiology

1- New High Blood Pressure Guidelines The wait is finally over: the high blood pressure guidelines that have been in the works for the past 3 years saw the light of day at the American Heart Association (AHA) 2017 Scientific Sessions. Read more  &nbsp; 2- New European Hypertension Guidelines Contrast with American Recommendations The European<a href="https://solaci.org/en/2019/01/21/the-most-relevant-articles-of-2018-in-pharmacology-and-clinical-cardiology/" title="Read more" >...</a>

Top